Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Forget the share price ... follow the bouncing H2S molecule
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(128)
•••
Comment by MrMugsyon Apr 23, 2021 9:51am
127 Views
Post# 33054397

RE:RE:RE:Forget the share price ... follow the bouncing H2S molecule

RE:RE:RE:Forget the share price ... follow the bouncing H2S molecule
WalkOverTheStrt wrote: Mugs - I'll ask Antibe to show us the money as in actually start a second human trial in a drug other than Oten... they can bs till pigs fly... We SHs and mgmt more importantly would be in an impressive position with HS2 validated or at least proven it is a platform (more than one human study early phase success).... Dan and mgmt failed to understand why this strategy was and is so important in current Oten partnership discussions... Tired of mgmt's bs.. deliver and execute...


I don't think we're going to get anything faster.
One main drug and in negotiations to partner - and that may require a year.
30 people work at ATE and I doubt they're going to pick up the speed ... thinking it will be a future partner or partners that carry the batton (but that's just my guess).

Unless - ATE brings in so much money to license OTENA that they start hiring for the purpose of running a bigger drug development business.  Don't know.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities